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Kathryn B. Garber1,*Fifty New Candidate Genes for Intellectual Disability
Progress in finding genes related to intellectual disability
(ID) has been faster on the X chromosome compared to
the rest of the genome because it is a much smaller target
area once families with likely X-linked inheritance are
identified. The development of strategies to capture and
sequence specific segments of the genome makes it
possible to do an analogous procedure with the auto-
somes. The problem then becomes which segments to
capture. Najmabadi et al. collected many consanguineous
Iranian families with intellectual disability (ID) and used
homozygosity mapping to suggest the regions for hybrid
capture and sequencing. This approach yielded a vast
increase in the number of genes likely to be involved in
autosomal-recessive ID, with plausible mutations identi-
fied in 115 of the 136 families in their study. Of these
genes, 23 had previously been implicated in ID or another
neurological disorder, but 50 are novel putative ID-associ-
ated genes. These include several genes involved in regu-
lation of transcription and translation, as well as some
that interact with known ID-associated genes. As has
been posited in the past, this research supports the
genetic heterogeneity of ID in the fact that only two of
the 50 novel ID genes were mutated in more than one
family.
Najmabadi et al. (2011). Nature 478, 57–63.
Hello Again
Some of you who attended the recent International
Congress of Human Genetics in Montreal may have been
fortunate enough to attend the debate session on the use
of next-generation sequencing technologies in clinical
practice. One of the ideas that came out of that session
was that a patient might have their genome or exome
sequenced to explain a particular health condition but
that the sequence data could be repeatedly mined for addi-
tional information throughout the life of the patient. An
interesting idea, for sure, but perhaps not as cut and dried
as it may at first seem. Reed Pyeritz recently published a
Perspective on the duty to recontact patients in the
context of the newer genetic testing technologies. He
explores such ideas as ‘‘Which physicians have the duty
to recontact a patient?’’ and ‘‘When is recontacting
a patient required?’’ The idea is simple: the more we learn
about genetic variation, the better we are able to interpret
genetic variation, but ensuring that this new information1Department of Human Genetics, Emory University School of Medicine, Atlan
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a challenge.
Pyeritz (2011). NEJM 365, 1367–1369.
A Trio of Papers on Trisomy and Triploidy
Descriptions of trisomy 13 and trisomy 18 can be found
in virtually every human genetics textbook, but in my
experience, they tend to be brief and not very optimistic.
This dearth of information makes it difficult to thor-
oughly counsel affected families on the prognosis of these
disorders. A trio of recent studies attempts to expand the
information available for these disorders, all from
different perspectives. The study by Lakovschek et al.
identified all cases of prenatally diagnosed trisomy 13,
trisomy 18, or triploidy in one department over the
course of 11 years and determined the outcome for each
of these cases. The majority of couples chose to terminate
these pregnancies, but of the pregnancies that were
continued, only 13% of pregnancies with trisomy 18,
33% of those with trisomy 13, and none of those with
triploidy resulted in a live birth. These babies were given
comfort care, and maximum survival was 87 hours.
Bruns, on the other hand, collected information on
long-term survivors of trisomy 13 by recruiting mothers
to complete an online survey. In this sample, the mean
survival time for children who died prior to the survey
was nearly 41 months, which was much longer than in
the first sample as a result of different recruitment strate-
gies. This survey also provides further information on the
physical characteristics and medical conditions experi-
enced by these individuals with trisomy 13. Finally,
Maeda et al. looked at the frequency of congenital heart
defects in trisomy 13 and trisomy 18, as well as the types
of cardiac surgery and the survival rates of these surgeries
in these patients. Although it is suggested that surgery
improves survival for trisomy 18, patients with more
complex congenital heart defects were not offered
surgery. This collection of data provides more complete
information for families and health care professionals
on the prognosis and management of these chromosome
disorders.
Bruns (2011). AJMG. Published online October 11, 2011.
10.1002/ajmg.a.34283; Lakovschek et al. AJMG. Published
online October 11, 2011. 10.1002/ajmg.a.34284; Maeda
et al. AJMG. Published online October 11, 2011. 10.1002/
ajmg.a.34285.ta, GA 30322, USA
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Keeping Up with the Times
As the pace of discovery in human genetics and genomics
becomes increasingly rapid, it can be hard to keep up with
everything. For a fresh-faced young scientist, it must be
downright daunting to be thrust right into the midst of
things with little framework on which to hang it all. I
thought the September 30 issue of Cell provided a great
introduction to certain topics for new scientists, while at
the same time giving more experienced folks a fresh
perspective. Starting with short notes from several geneti-
cists on what they think are the biggest surprises uncov-
ered in the human genome so far, the issue continues
with two commentaries, one by Teri Manolio and Eric
Green and one by David Ginsburg, on the movement of
genomics into the clinic. Also therein is a primer by Sou-
mya Raychaudhuri on mapping both common and rare
variation in complex disease and an overview, by Herbert
Virgin and John Todd, of the interaction of the human
genome with the microbiome and their joint contribution
to complex diseases such as type 1 diabetes and ulcerative
colitis. A review of the ciliopathies by Joe Gleeson’s group
lends understanding to the ways in which human disease
gene discovery can translate into a better understanding
of disease pathogenesis, and the issue is rounded out594 The American Journal of Human Genetics 89, 593–594, Novembwith a perspective by Jim Lupski and colleagues, who
contribute their thoughts on the architecture of genetic
disease. Finally, don’t miss the Snapshot, which is a nice
glossary of terms in human genomics.
Various authors (2011). Cell 147(1).
The Mystery of the Disappearing Mitochondria
Although sperm clearly have mitochondria to power them
along, fathers don’t make a contribution to the mitochon-
drial complement of their children. This gives rise to the
maternal lineage of mitochondrial inheritance. Paternal
mitochondria do enter into the oocyte, though, so what
happens to them? Do they simply get swamped out by
the larger number of copies of the oocyte mitochondria,
or do they meet some other fate? Sato and Sato recently
studied this in C. elegans, and they found that penetration
by sperm triggers an autophagic response that localizes
around the paternal mitochondria, which are then sent
to the lysosomes for degradation. Worms mutant for auto-
phagy regulators are defective in this degradation, and the
result in these mutants is paternal inheritance of mito-
chondria.
Sato and Sato (2011). Science Express. Published online
October 13, 2011. 10.1126/science.1210333.This Month in Our Sister JournalsClinical Validation Study of a Noninvasive Detection
Method for Down Syndrome
Prenatal diagnosis via high-throughput sequencing of cell-
free fetal DNA in maternal plasma has been bandied about
for a few years but has had some problems making its way
into clinical practice. The basic idea is to look for an over-
representation of sequences from chromosome 21 in cell-
free DNA in order to identify trisomy 21. The promise of
this technique is that its potential for increased detection
of affected pregnancies could reduce the number of inva-
sive prenatal diagnostic tests that are performed, thereby
reducing the likelihood of procedure-related fetal loss. Pal-
omaki et al. recently completed a blinded case-control
study that supports this idea. Their study was designed to
assess the clinical validity of this detection method in
a sample of pregnant women at high risk for Downsyndrome. They compared fetal karyotype results with
those from this next-generation sequencing approach in
order to assess how well the new method does compared
to the gold standard, fetal karyotype. The noninvasive
method yielded a detection rate for Down syndrome of
98.6%, with a false-positive rate of just 0.2%, which is
a substantial improvement over current prenatal screening
methodologies. This method cannot yet replace invasive
prenatal diagnostic testing, but—if implemented in high-
risk women prior to the decision to have invasive
testing—it has the potential to reduce procedure-related
fetal losses by 96%. Following this publication, Sequenom
announced that it has launched this test in several metro-
politan areas.
Palomaki et al. (2011). Genetics in Medicine. Published
online October 14, 2011. 10.1097/GIM0b013e3182368a0e.er 11, 2011
